Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INDP NASDAQ:TNFA NASDAQ:UPC NASDAQ:XBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINDPIndaptus Therapeutics$2.17+3.8%$2.19$1.51▼$19.91$4.82M1.3764,767 shs8,377 shsTNFATNF Pharmaceuticals$3.81+0.5%$3.73$0.04▼$8.94$7.04M2.0432.22 million shs213,565 shsUPCUniverse Pharmaceuticals$2.88-6.4%$2.84$2.00▼$11.00$1.61M1.5813,480 shs11,493 shsXBIOXenetic Biosciences$3.16+2.1%$2.90$1.90▼$13.93$7.22M2.222,640 shs7,317 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINDPIndaptus Therapeutics-2.34%-35.89%+30.63%+16.76%-83.81%TNFATNF Pharmaceuticals+1.61%-4.29%+9.54%-3.07%-80.43%UPCUniverse Pharmaceuticals-4.36%+2.33%-2.85%-30.07%+306,999,900.00%XBIOXenetic Biosciences+3.55%-0.32%+2.66%+41.74%+10.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINDPIndaptus Therapeutics$2.17+3.8%$2.19$1.51▼$19.91$4.82M1.3764,767 shs8,377 shsTNFATNF Pharmaceuticals$3.81+0.5%$3.73$0.04▼$8.94$7.04M2.0432.22 million shs213,565 shsUPCUniverse Pharmaceuticals$2.88-6.4%$2.84$2.00▼$11.00$1.61M1.5813,480 shs11,493 shsXBIOXenetic Biosciences$3.16+2.1%$2.90$1.90▼$13.93$7.22M2.222,640 shs7,317 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINDPIndaptus Therapeutics-2.34%-35.89%+30.63%+16.76%-83.81%TNFATNF Pharmaceuticals+1.61%-4.29%+9.54%-3.07%-80.43%UPCUniverse Pharmaceuticals-4.36%+2.33%-2.85%-30.07%+306,999,900.00%XBIOXenetic Biosciences+3.55%-0.32%+2.66%+41.74%+10.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINDPIndaptus Therapeutics 1.00SellN/AN/ATNFATNF Pharmaceuticals 1.00SellN/AN/AUPCUniverse Pharmaceuticals 1.00SellN/AN/AXBIOXenetic Biosciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest UPC, INDP, TNFA, and XBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026UPCUniverse Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026INDPIndaptus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026XBIOXenetic Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINDPIndaptus TherapeuticsN/AN/AN/AN/A$1.40 per shareN/ATNFATNF PharmaceuticalsN/AN/AN/AN/A$286.76 per shareN/AUPCUniverse Pharmaceuticals$17.86M0.09N/AN/A$99.64 per share0.03XBIOXenetic Biosciences$2.98M2.42N/AN/A$3.23 per share0.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINDPIndaptus Therapeutics-$20.85M-$24.13N/AN/AN/AN/A-939.67%-293.64%5/7/2026 (Estimated)TNFATNF Pharmaceuticals-$23.36M-$231.00N/AN/AN/AN/A-69.21%-33.98%N/AUPCUniverse Pharmaceuticals-$3.67MN/AN/AN/AN/AN/AN/AN/AN/AXBIOXenetic Biosciences-$2.68M-$1.59N/AN/AN/A-90.09%-51.27%-43.63%5/7/2026 (Estimated)Latest UPC, INDP, TNFA, and XBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026N/AINDPIndaptus Therapeutics-$1.87N/AN/AN/AN/AN/A3/17/2026Q4 2025INDPIndaptus Therapeutics-$4.36-$3.10+$1.26-$3.10N/AN/A3/12/2026Q4 2025XBIOXenetic Biosciences-$0.52-$0.22+$0.30-$0.22$0.69 million$0.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINDPIndaptus TherapeuticsN/A1.511.51TNFATNF PharmaceuticalsN/A0.930.93UPCUniverse PharmaceuticalsN/A4.073.90XBIOXenetic BiosciencesN/A8.328.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINDPIndaptus Therapeutics7.06%TNFATNF Pharmaceuticals9.64%UPCUniverse Pharmaceuticals0.18%XBIOXenetic Biosciences15.12%Insider OwnershipCompanyInsider OwnershipINDPIndaptus Therapeutics23.60%TNFATNF Pharmaceuticals0.45%UPCUniverse Pharmaceuticals57.38%XBIOXenetic Biosciences7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINDPIndaptus Therapeutics62.24 million1.71 millionNot OptionableTNFATNF Pharmaceuticals61.85 million1.84 millionN/AUPCUniverse Pharmaceuticals220560,000240,000N/AXBIOXenetic Biosciences42.29 million2.12 millionNot OptionableUPC, INDP, TNFA, and XBIO HeadlinesRecent News About These CompaniesXenetic Biosciences Grants Equity Award to Interim CEOApril 27, 2026 | theglobeandmail.comXenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual MeetingApril 22, 2026 | accessnewswire.comAXenetic Biosciences, Inc. Reports Full Year 2025 Financial ResultsMarch 13, 2026 | accessnewswire.comAXenetic Biosciences, Inc. Announces Adjournment of 2025 Annual MeetingDecember 11, 2025 | accessnewswire.comAXenetic extends R&D collaboration with The Scripps Research InstituteNovember 19, 2025 | msn.comXenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase PlatformNovember 19, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Reports Third Quarter 2025 Financial ResultsNovember 13, 2025 | accessnewswire.comAXenetic Biosciences Announces Public Offering PricingOctober 14, 2025 | msn.comXenetic 735,000 share Spot Secondary priced at $6.12October 10, 2025 | msn.comMicron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking SurgesOctober 10, 2025 | benzinga.comXenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common StockOctober 10, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | accessnewswire.comAXenetic Biosciences Reports Improved Financial PerformanceAugust 13, 2025 | msn.comXenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue EstimatesAugust 12, 2025 | zacks.comXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell LymphomaJuly 30, 2025 | accessnewswire.comAXenetic Biosciences expands R&D collaboration with The Scripps Research Institute to advance DNase platformJuly 26, 2025 | pharmabiz.comPXenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformJuly 23, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the ...July 8, 2025 | finanznachrichten.deXenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic CancerJuly 8, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIntel Went From Market Reject to Musk's AI Partner — What Happens Next?By Sam Quirke | April 13, 2026Is Oracle Undervalued as Cloud Growth Accelerates?By Thomas Hughes | April 29, 2026Storm Warning? Rivian's Real Test Is Not a TornadoBy Jeffrey Neal Johnson | April 22, 2026Kinder Morgan’s Cash Flow Drives Upside: Potential Swells in Q1By Thomas Hughes | April 24, 2026Avis Short Squeeze Shocked the Market: Are These 3 Stocks Next?By Dan Schmidt | April 27, 2026UPC, INDP, TNFA, and XBIO Company DescriptionsIndaptus Therapeutics NASDAQ:INDP$2.17 +0.08 (+3.78%) As of 11:57 AM Eastern This is a fair market value price provided by Massive. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.TNF Pharmaceuticals NASDAQ:TNFA$3.81 +0.02 (+0.53%) As of 05/5/2026TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Universe Pharmaceuticals NASDAQ:UPC$2.88 -0.20 (-6.35%) As of 11:50 AM Eastern This is a fair market value price provided by Massive. Learn more.Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.Xenetic Biosciences NASDAQ:XBIO$3.16 +0.07 (+2.10%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
